Immediate Management: Stop IVIG and Assess for Thrombotic Emergency
If a patient develops sudden bluish discoloration during IVIG infusion for Kawasaki disease, immediately stop the infusion and evaluate for thrombosis, as this represents a potentially life-threatening complication of IVIG therapy. The bluish discoloration (cyanosis) suggests either arterial thrombosis with limb ischemia or severe hyperviscosity syndrome—both are recognized serious adverse events of IVIG administration 1.
Immediate Actions (Within Minutes)
Stop the IVIG infusion immediately and do not restart until the cause is identified 1.
Assess the Clinical Picture:
- Location of discoloration: Is it localized (suggesting arterial thrombosis) or generalized (suggesting hypoxia/cardiac compromise)?
- Vital signs: Check blood pressure, heart rate, oxygen saturation, and respiratory status
- Perfusion markers: Assess capillary refill, temperature of affected area, and presence of pulses
- Neurological status: Rule out stroke if facial or unilateral involvement
Critical Laboratory Assessment:
- Blood viscosity indicators: Obtain immediate hematocrit, total protein, and serum IgG levels 2
- Coagulation studies: PT/PTT, D-dimer, fibrinogen
- Renal function: BUN and creatinine (IVIG can cause acute renal failure) 1
- Cardiac markers: If cardiac compromise suspected
Differential Diagnosis and Specific Management
If Arterial Thrombosis (Localized Bluish Discoloration):
This is particularly concerning in Kawasaki disease patients who may already have coronary involvement. Thrombosis risk is heightened by IVIG-induced hyperviscosity 1.
Management approach:
- Urgent vascular surgery or interventional radiology consultation
- Consider immediate anticoagulation with heparin plus aspirin 3
- Urgent imaging (Doppler ultrasound or CT angiography) of affected area
- For coronary thrombosis: Consider abciximab (platelet glycoprotein IIb/IIIa inhibitor) 3
If Hyperviscosity Syndrome (Generalized Symptoms):
IVIG can cause hyperproteinemia and increased serum viscosity, particularly in older/larger children receiving weight-based dosing 2.
Management approach:
- Aggressive hydration with isotonic fluids 1
- Monitor serum IgG levels—if markedly elevated (>2000-2500 mg/dL), consider holding further IVIG 2
- In severe cases, consider plasma exchange 3
If Hypersensitivity/Anaphylaxis:
Severe hypersensitivity can cause cardiovascular collapse with resultant cyanosis 1.
Management approach:
- Administer epinephrine if anaphylaxis suspected
- IV fluids for blood pressure support
- Antihistamines and corticosteroids
- Note: Flebogamma 5% DIF contains trace IgA (<50 μg/mL); patients with anti-IgA antibodies are at higher risk 1
Resuming Kawasaki Disease Treatment
If IVIG Cannot Be Continued:
The American Heart Association guidelines provide alternatives for IVIG-refractory or intolerant patients 3:
- Corticosteroids: Intravenous methylprednisolone 30 mg/kg over 2-3 hours daily for 1-3 days (evidence level C) 3
- Infliximab: Consider for patients who cannot tolerate IVIG (evidence level C) 3
- Plasma exchange: Reserved for severe refractory cases due to risks (evidence level C) 3
If IVIG Can Be Resumed:
- Ensure adequate hydration before restarting 1
- Slow the infusion rate: Start at minimum rate (0.01 mL/kg/min) and increase gradually only if tolerated 1
- Monitor continuously for recurrence
- In older/larger children, consider monitoring serum IgG levels and adjusting total dose if levels become excessively elevated 2
Critical Pitfalls to Avoid
Do not assume the discoloration is unrelated to IVIG: Thrombosis is a known, serious complication that can occur even without traditional risk factors 1
Do not restart IVIG at the same rate: If resuming, always start at the minimum infusion rate 1
Do not ignore renal function: IVIG can cause acute renal failure; check BUN/creatinine before any additional IVIG 1
Do not delay anticoagulation if thrombosis confirmed: Kawasaki disease patients with coronary aneurysms and thrombosis require immediate heparin plus aspirin 3
Do not use adult dose caps for IVIG in older children without monitoring: Weight-based dosing at 2 g/kg can lead to excessive IgG levels and hyperviscosity in larger patients 2
The priority is preventing mortality from thrombotic complications while still treating the underlying Kawasaki disease to prevent coronary artery aneurysms. This requires immediate recognition, cessation of the offending agent, and rapid assessment for life-threatening complications.